AVADEL PHARMACEUTICALS PLC (NASDAQ:AVDL) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
On March 7, 2017, Avadel Pharmaceuticals PLC (the Company) issued
a press release announcing its earnings for the quarter ended
December 31, 2016. That press release is attached as Exhibit 99.1
and is incorporated herein by reference.
a press release announcing its earnings for the quarter ended
December 31, 2016. That press release is attached as Exhibit 99.1
and is incorporated herein by reference.
The information responsive to this Item 2.02 of this Form 8-K,
including Exhibit 99.1, shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934 (the Exchange
Act) or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933 (the Securities Act) or the Exchange
Act, except as may be expressly set forth by specific reference
in such a filing.
including Exhibit 99.1, shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934 (the Exchange
Act) or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933 (the Securities Act) or the Exchange
Act, except as may be expressly set forth by specific reference
in such a filing.
Item 7.01 Regulation FD Disclosure.
On March 7, 2017, the Company posted to its website a set of
presentation materials that it will use during its earnings call
and webcast to assist participants with understanding the
Companys financial results for the quarter ended December 31,
2016. A copy of this presentation is attached hereto as Exhibit
99.2.
presentation materials that it will use during its earnings call
and webcast to assist participants with understanding the
Companys financial results for the quarter ended December 31,
2016. A copy of this presentation is attached hereto as Exhibit
99.2.
The information responsive to this Item 7.01 of this Form 8-K,
including Exhibit 99.2, shall not be deemed filed for purposes of
Section 18 of the Exchange Act or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act or the
Exchange Act, except as may be expressly set forth by specific
reference in such a filing.
including Exhibit 99.2, shall not be deemed filed for purposes of
Section 18 of the Exchange Act or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act or the
Exchange Act, except as may be expressly set forth by specific
reference in such a filing.
Item 8.01 Other Events.
On March 7, 2017, Avadel Pharmaceuticals plc issued a press
releases announcing that the Companys Board of Directors
authorized a share repurchase program of up to $25 million of the
Companys ordinary shares, represented by American Depository
Shares (ADS) which are listed for trading on the NASDAQ Global
Market. Repurchases may be made in open-market transactions,
block transactions on or off the exchange, in privately
negotiated transactions, or through other means as determined by
Avadels management and in accordance with the regulations of the
Securities and Exchange Commission. A copy of this release is
furnished as Exhibit 99.3 to this current report on Form 8-K and
is incorporated herein by reference
releases announcing that the Companys Board of Directors
authorized a share repurchase program of up to $25 million of the
Companys ordinary shares, represented by American Depository
Shares (ADS) which are listed for trading on the NASDAQ Global
Market. Repurchases may be made in open-market transactions,
block transactions on or off the exchange, in privately
negotiated transactions, or through other means as determined by
Avadels management and in accordance with the regulations of the
Securities and Exchange Commission. A copy of this release is
furnished as Exhibit 99.3 to this current report on Form 8-K and
is incorporated herein by reference
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
99.1
|
Press release dated March 7, 2017, issued by Avadel
Pharmaceuticals plc * |
|
|
99.2
|
Presentation materials *
|
|
|
99.3
|
Press release dated March 7, 2017, issued by Avadel
Pharmaceuticals plc |
* This information shall be deemed to be “furnished” and not
filed herewith.
filed herewith.
AVADEL PHARMACEUTICALS PLC (NASDAQ:AVDL) Recent Trading Information
AVADEL PHARMACEUTICALS PLC (NASDAQ:AVDL) closed its last trading session up +0.14 at 10.20 with 462,869 shares trading hands.
